Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Mon, 08th Feb 2021 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Omega Diagnostics, up 40% at 96.98 pence, 12-month range 5.93p-126.95p. It will continue to modify its Alva-based facility to "upscale significantly" its lateral flow test production capacity as it noted a Financial Times article. The FT said the UK government has chosen three British companies to make rapid Covid-19 tests. The newspaper said Omega, SureScreen and Global Access Diagnostics have been selected by the Department of Health to produce up to 2 million lateral flow devices per day for the UK, according to two people briefed on the decision.

----------

Avacta Group, up 6.8% at 136.20 pence, 12-month range 13.00p-215.25p. Says it has entered into a commercial partnership with Mologic to accelerate to market Avacta's AffiDX SARS-CoV-2 lateral flow rapid antigen test. The pre-clinical stage biotechnology company said the partnership will provide the AffiDX antigen test a faster route to market by giving it a CE marking for professional use under rapid diagnostics firm Mologic's ISO13485 quality system.

----------

Tower Resources, up 11% at 0.56 pence, 12-month range 0.189p-0.650p. Notes its South African unit Rift Petroleum has received an updated resource at the offshore Algoa-Gamtoos license from partner New Age Energy Algoa. After reprocessing seismic data at the asset, overall portfolio volumes are 54% higher at Algoa-Gamtoos, Tower explained.

----------

AIM - LOSERS

----------

Bahamas Petroleum, down 67% at 0.68p, 12-month range 0.500p-5.722p. Bahamas said that while the Perseverance #1 well encountered hydrocarbons, commercial volumes of oil were not proven. The company said the Perseverance #1 well in the Bahamas encountered hydrocarbons, as well as successfully validating the structural model and the petroleum system. However, volumes of oil encountered "are not commercial".

----------

Tissue Regenix, down 12% at 0.65p, 12-month range 0.275p-1.280p. The company expects a revenue fall in 2020, citing the negative impact of the Covid-19 pandemic. The medical devices company expects revenue of GBP12.8 million, down 1.5% from 2019's GBP13.0 million. Its financial performance was "impacted by the ongoing coronavirus pandemic".

----------

Inland Homes, down 10% at 57.75p, 12-month range 32.00p-89.85p. The company reported a fall in full-year profit as activity was disrupted by the coronavirus pandemic. Its EPRA net asset value per share at the end of September 2020 was 103.97 pence per share, down 8.5% on a year ago due to a placing of 20.8 million new shares during the year. In a separate release, Inland Homes said Chair Terry Roydon will be standing down from the board at the conclusion of the company's annual general meeting in March. Senior Independent Director Simon Bennett will be promoted to chair,

----------

boohoo Group, down 4.5% at 348.40p, 12-month range 133.10p-433.50p. The AIM-listed online-only fashion retailer will be buying the e-commerce and digital assets and associated intellectual property rights, including customer data, related business information and inventory, of the Burton, Dorothy Perkins and Wallis brands. The GBP25.2 million deal to acquire the former Arcadia Group brands does not include any stores. boohoo said Monday's acquisition is a "significant opportunity to grow" its market share.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

Read more
28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Read more
28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

Read more
10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Read more
22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Read more
20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

Read more
20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Read more
20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

Read more
15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Read more
6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

Read more
25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Read more
9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Read more
9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

Read more
8 Mar 2021 19:07

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.